Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2060 single-dose in Japanese older ESRD patients
NCT05769595Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thrombosis comparing MK-2060 Arm with Placebo Arm (2 arms). Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) up to 164 days and Number of Participants Who Discontinued Study Due to an AE up to 164 days. Started Jun 2023; status: completed.
02
Drugs
MK-2060
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT05769595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769595.